Cardiovascular risk estimation and eligibility for statins in primary prevention comparing different strategies.
Recommendations for statin use for primary prevention of coronary heart disease (CHD) are based on estimation of the 10-year CHD risk. It is unclear which risk algorithm and guidelines should be used in European populations. Using data from a population-based study in Switzerland, we first assessed 10-year CHD risk and eligibility for statins in 5,683 women and men 35 to 75 years of age without cardiovascular disease by comparing recommendations by the European Society of Cardiology without and with extrapolation of risk to age 60 years, the International Atherosclerosis Society, and the US Adult Treatment Panel III. The proportions of participants classified as high-risk for CHD were 12.5% (15.4% with extrapolation), 3.0%, and 5.8%, respectively. Proportions of participants eligible for statins were 9.2% (11.6% with extrapolation), 13.7%, and 16.7%, respectively. Assuming full compliance to each guideline, expected relative decreases in CHD deaths in Switzerland over a 10-year period would be 16.4% (17.5% with extrapolation), 18.7%, and 19.3%, respectively; the corresponding numbers needed to treat to prevent 1 CHD death would be 285 (340 with extrapolation), 380, and 440, respectively. In conclusion, the proportion of subjects classified as high risk for CHD varied over a fivefold range across recommendations. Following the International Atherosclerosis Society and the Adult Treatment Panel III recommendations might prevent more CHD deaths at the cost of higher numbers needed to treat compared with European Society of Cardiology guidelines.
Department of Ambulatory Care and Community Medicine, University Hospital Centre, University of Lausanne, Switzerland. david.nanchen@chuv.ch
David
D
Nanchen
Arnaud
A
Chiolero
Jacques
J
Cornuz
Pedro-Manuel
PM
Marques-Vidal
Mathieu
M
Firmann
Vincent
V
Mooser
Fred
F
Paccaud
Gérard
G
Waeber
Peter
P
Vollenweider
Nicolas
N
Rodondi
D000328:Adult; D000368:Aged; D003327:Coronary Disease / Q000517:prevention & control*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment; D013557:Switzerland
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors